WEST PALM BEACH, Fla, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) (OTC: RNVAW), today announced that it has purchased and taken delivery of equipment to provide rapid testing for Coronavirus Disease 2019 (COVID-19) at three sites, two of its hospitals in East Tennessee and its rural clinic in Kentucky.
Rennova entered an agreement with Abbott laboratories to install and provide the ID NOW testing to our facilities. ID NOW provides results in 15 minutes utilizing state of the art molecular techniques (isothermal amplification of viral RNA). This test is approved under U.S. Food and Drug Administration Emergency Use Authorization (EUA) from direct nasal or noso-pharyngeal swabs. Testing is expected to begin in September at all 3 facilities. Patients may come to the facilities at their own wish or with a doctor's order for the testing and leave with a result.
“It has become apparent that for diagnosing and managing COVID-19, laboratory testing should provide rapid and sensitive results on a same-day, current status of an individual regarding infection by the SARS-CoV-2” said Seamus Lagan, CEO of Rennova Health, Inc. “Particularly in acute settings such as emergency rooms, primary care visits, and surgery a fast result is necessary. We believe this investment in a FDA approved COVID-19 rapid test offers an excellent solution that can be used by our patients and the community and offered to a broader population in coming months”
About Rennova Health, Inc.
Rennova owns three rural hospitals and a physician’s office in Tennessee and a rural clinic in Kentucky, and provides industry-leading diagnostics and supportive software solutions to healthcare providers. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Contacts:
Rennova Health
Sebastien Sainsbury
561-666-9818
ssainsbury@rennovahealth.com
# # #